219 related articles for article (PubMed ID: 15207782)
1. Fas ligand-dependent suppression of autoimmunity via recruitment and subsequent termination of activated T cells.
Modiano JF; Sun J; Lang J; Vacano G; Patterson D; Chan D; Franzusoff A; Gianani R; Meech SJ; Duke R; Bellgrau D
Clin Immunol; 2004 Jul; 112(1):54-65. PubMed ID: 15207782
[TBL] [Abstract][Full Text] [Related]
2. Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer.
Zhang H; Yang Y; Horton JL; Samoilova EB; Judge TA; Turka LA; Wilson JM; Chen Y
J Clin Invest; 1997 Oct; 100(8):1951-7. PubMed ID: 9329958
[TBL] [Abstract][Full Text] [Related]
3. T cell dependent and independent antitumor immunity generated by the expression of Fas ligand on mouse lung carcinoma cells.
Tada Y; O-Wang J; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
Int J Mol Med; 2002 Mar; 9(3):281-5. PubMed ID: 11836634
[TBL] [Abstract][Full Text] [Related]
4. Effective treatment of established mouse collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express FasL.
Kim SH; Kim S; Oligino TJ; Robbins PD
Mol Ther; 2002 Nov; 6(5):584-90. PubMed ID: 12409256
[TBL] [Abstract][Full Text] [Related]
5. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo.
Rensing-Ehl A; Frei K; Flury R; Matiba B; Mariani SM; Weller M; Aebischer P; Krammer PH; Fontana A
Eur J Immunol; 1995 Aug; 25(8):2253-8. PubMed ID: 7545115
[TBL] [Abstract][Full Text] [Related]
6. Exosomes derived from genetically modified DC expressing FasL are anti-inflammatory and immunosuppressive.
Kim SH; Bianco N; Menon R; Lechman ER; Shufesky WJ; Morelli AE; Robbins PD
Mol Ther; 2006 Feb; 13(2):289-300. PubMed ID: 16275099
[TBL] [Abstract][Full Text] [Related]
7. Ultraviolet light-induced immune tolerance is mediated via the Fas/Fas-ligand system.
Schwarz A; Grabbe S; Grosse-Heitmeyer K; Roters B; Riemann H; Luger TA; Trinchieri G; Schwarz T
J Immunol; 1998 May; 160(9):4262-70. PubMed ID: 9574528
[TBL] [Abstract][Full Text] [Related]
8. B lymphocytes mediate Fas-dependent cytotoxicity in MRL/lpr mice.
Bonardelle D; Benihoud K; Kiger N; Bobé P
J Leukoc Biol; 2005 Nov; 78(5):1052-9. PubMed ID: 16204618
[TBL] [Abstract][Full Text] [Related]
9. Engagement of CD44 up-regulates Fas ligand expression on T cells leading to activation-induced cell death.
Nakano K; Saito K; Mine S; Matsushita S; Tanaka Y
Apoptosis; 2007 Jan; 12(1):45-54. PubMed ID: 17136494
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects are produced by forced expression of membrane-bound but not soluble Fas ligand in murine lung carcinoma cells.
Tada Y; O-Wang J; Seimiya M; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
Anticancer Res; 2002; 22(2A):831-6. PubMed ID: 12014659
[TBL] [Abstract][Full Text] [Related]
11. Evidence for Fas-dependent and Fas-independent mechanisms in the pathogenesis of experimental autoimmune encephalomyelitis.
Dittel BN; Merchant RM; Janeway CA
J Immunol; 1999 Jun; 162(11):6392-400. PubMed ID: 10352252
[TBL] [Abstract][Full Text] [Related]
12. Fas ligand exerts its pro-inflammatory effects via neutrophil recruitment but not activation.
Dupont PJ; Warrens AN
Immunology; 2007 Jan; 120(1):133-9. PubMed ID: 17233740
[TBL] [Abstract][Full Text] [Related]
13. Ameliorating effect of anti-Fas ligand MAb on wasting disease in murine model of chronic colitis.
Dan N; Kanai T; Totsuka T; Iiyama R; Yamazaki M; Sawada T; Miyata T; Yagita H; Okumura K; Watanabe M
Am J Physiol Gastrointest Liver Physiol; 2003 Oct; 285(4):G754-60. PubMed ID: 12969829
[TBL] [Abstract][Full Text] [Related]
14. Amelioration of lymphoid hyperplasia and hypergammaglobulinemia in lupus-prone mice (gld) by Fas-ligand gene transfer.
Hong NM; Masuko-Hongo K; Sasakawa H; Kato T; Shirai T; Okumura K; Nishioka K; Kobata T
J Autoimmun; 1998 Aug; 11(4):301-7. PubMed ID: 9776707
[TBL] [Abstract][Full Text] [Related]
15. Fas ligand-expressing tumors induce tumor-specific protective immunity in the inoculated hosts but vaccination with the apoptotic tumors suppresses antitumor immunity.
Tada Y; O-Wang J; Wada A; Takiguchi Y; Tatsumi K; Kuriyama T; Sakiyama S; Tagawa M
Cancer Gene Ther; 2003 Feb; 10(2):134-40. PubMed ID: 12536202
[TBL] [Abstract][Full Text] [Related]
16. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors decrease Fas ligand expression and cytotoxicity in activated human T lymphocytes.
Blanco-Colio LM; Muñoz-García B; Martín-Ventura JL; Lorz C; Díaz C; Hernández G; Egido J
Circulation; 2003 Sep; 108(12):1506-13. PubMed ID: 12952848
[TBL] [Abstract][Full Text] [Related]
17. B cells engineered to express Fas ligand suppress pre-sensitized antigen-specific T cell responses in vivo.
Kosiewicz MM; Krishnan A; Worthington MT; Matriano JA; Ross WG
Eur J Immunol; 2002 Jun; 32(6):1679-87. PubMed ID: 12115651
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous stimulation of Fas-mediated apoptosis and blockade of costimulation prevent autoimmune diabetes in mice induced by multiple low-dose streptozotocin.
Jin Y; Qu A; Wang GM; Hao J; Gao X; Xie S
Gene Ther; 2004 Jun; 11(12):982-91. PubMed ID: 15042121
[TBL] [Abstract][Full Text] [Related]
19. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
Ryan AE; Shanahan F; O'Connell J; Houston AM
Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
[TBL] [Abstract][Full Text] [Related]
20. Immune privilege or inflammation? The paradoxical effects of Fas ligand.
O'Connell J
Arch Immunol Ther Exp (Warsz); 2000; 48(2):73-9. PubMed ID: 10807046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
